Outcomes of 3 patients with adenosine deaminase deficiency on long-term enzyme replacement therapy

Ann Allergy Asthma Immunol. 2021 May;126(5):593-595. doi: 10.1016/j.anai.2020.12.008. Epub 2021 Jan 30.

Authors

Melissa D Gans¹, Larry Bernstein², Jenny Shliozberg², Tatyana Gavrilova², Arye Rubinstein²

Affiliations

¹ Division of Pediatric Pulmonology, Allergy, Immunology, and Sleep Medicine, Westchester Medical Center/Boston Children's Health Physicians, New York Medical College, Hawthorne, New York. Electronic address: melissagansmd@gmail.com.
² Division of Allergy and Immunology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.

PMID: 33359138
DOI: 10.1016/j.anai.2020.12.008

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenosine Deaminase / deficiency
Adult
Agammaglobulinemia / drug therapy*
Enzyme Replacement Therapy / methods*
Humans
Hydrolases / therapeutic use*
Male
Polyethylene Glycols / therapeutic use*
Severe Combined Immunodeficiency / drug therapy*
Treatment Outcome

Substances

Polyethylene Glycols
Hydrolases
ADI PEG20
Adenosine Deaminase

Supplementary concepts

Severe combined immunodeficiency due to adenosine deaminase deficiency